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Abstract
Cyclooxygenase-2 (COX-2) expression has been detected in human hepatoma cell lines and in human hepatocellular
carcinoma (HCC); however, the contribution of COX-2 to the development of HCC remains controversial. COX-2 expression
is higher in the non-tumoral tissue and inversely correlates with the differentiation grade of the tumor. COX-2 expression
depends on the interplay between different cellular pathways involving both transcriptional and post-transcriptional
regulation. The aim of this work was to assess whether COX-2 could be regulated by microRNAs in human hepatoma cell
lines and in human HCC specimens since these molecules contribute to the regulation of genes implicated in cell growth
and differentiation. Our results show that miR-16 silences COX-2 expression in hepatoma cells by two mechanisms: a) by
binding directly to the microRNA response element (MRE) in the COX-2 39-UTR promoting translational suppression of COX-
2 mRNA; b) by decreasing the levels of the RNA-binding protein Human Antigen R (HuR). Furthermore, ectopic expression of
miR-16 inhibits cell proliferation, promotes cell apoptosis and suppresses the ability of hepatoma cells to develop tumors in
nude mice, partially through targeting COX-2. Moreover a reduced miR-16 expression tends to correlate to high levels of
COX-2 protein in liver from patients affected by HCC. Our data show an important role for miR-16 as a post-transcriptional
regulator of COX-2 in HCC and suggest the potential therapeutic application of miR-16 in those HCC with a high COX-2
expression.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and has an increasing incidence in western
countries [1]. Although the risk factors for HCC are well
characterized, the molecular pathogenesis of this tumor type is
not well understood [2,3], and thus the identification of new
possible targets for the development of non-conventional treat-
ments is urgent and must be improved.
Cyclooxygenase-1 (COX-1) and -2 catalyze the first step in
prostanoid biosynthesis. COX-1 is constitutively expressed in
many tissues, whereas COX-2 is induced by a variety of stimuli
such as growth factors, pro-inflammatory stimuli, hormones and
other cellular stresses [4]. Adult hepatocytes fail to induce COX-2
expression regardless of the pro-inflammatory factors used [5,6].
However, our group and others demonstrated that partial
hepatectomy (PH) [7,8] induced COX-2 in hepatocytes and
contributed to the progression of cell cycle after PH. In addition to
liver regeneration after PH or hepatotoxic agents, expression of
COX-2 has been detected in animal models of cirrhosis [9], in
human hepatoma cell lines [10,11], in human HCC [12] and after
HBV and HCV infection [13,14].
COX-2 is widely regarded as a potential pharmacological target
for preventing and treating inflammatory and cancer diseases.
Therapeutic strategies have focused primarily on selective
inhibitors of COX-2 activity; however, considerable less attention
has been paid to identifying anticancer agents that suppress the
expression of COX-2 [15]. COX-2 overexpression is the result of
the activation of many intracellular pathways that regulate COX-2
both at transcriptional and post-transcriptional level. The 59-UTR
of the COX-2 gene contains binding sites for numerous regulatory
transcription factors including two NF-kB (nuclear factor kB)
motifs, two AP-1 (activator protein 1) sites and two CREs (cAMP-
response elements) among others [16]. However, the regulation of
the expression of COX-2 is more complex including modifications
of genomic DNA and chromatin and at the post-transcriptional
level via targeting its 39-UTR [17]. The 39-UTR of COX-2
contains multiple copies of AU-rich elements (AREs) and
microRNA response element (MRE) motifs which, when bound
by specific ARE-binding factors or miRNAs, influence COX-2
stability and translational efficiency [17].
MicroRNAs (miRNAs) are short single-stranded non-coding
RNAs that influence post-transcriptional gene regulation by
affecting mRNA stability and/or translational repression of their
target mRNAs [18]. Alterations of the expression pattern of
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miRNAs that regulate genes involved in cellular proliferation,
differentiation or apoptosis, have been found in different human
tumors including HCC [19,20], suggesting that they may
represent a novel class of oncogenes or tumor suppressor genes.
Moreover, recent reports of profound phenotypic abnormalities in
miRNA-knockout models further demonstrate their crucial roles
as regulators of gene expression [21]. Regarding COX-2, Dey’s
group [22,23] highlighted a miRNA-mediated regulation of COX-
2 by mmu-miR-101a and mmu-miR-199a* during embryo
implantation and in endometrial cancer cells. Recent works have
reported that miR-101 downregulation is involved in COX-2
overexpression in human colon cancer cells (CRC) [24], miRNA-
26b regulates the expression of COX-2 in desferrioxamine-treated
carcinoma of nasopharyngeal epithelial cells [25] and binding of
miR-16 to AREs of TNF-a, IL-6, IL-9 and COX-2 mRNA
transcripts could promote their degradation [20,26].
Besides miRNAs, various cytoplasmic proteins have been
reported to bind the COX-2 39UTR [20]. As an example, the
RNA-binding protein CUGBP2 interacts directly with specific
AREs within the first 60 nucleotides of the COX-2 39-UTR and
that binding stabilizes the COX-2 mRNA yet inhibits its
translation [27]; tristetrapolin binds to COX-2 39UTR and
decrease mRNA levels in colon cancer [28], whereas Human
Antigen R (HuR) is a translational enhancer of COX-2 in ovarian
carcinoma [29] and in colon carcinogenesis [20].
To our knowledge, no data is available concerning the post-
transcriptional regulation of COX-2 by miRNAs and RNA-
binding proteins in HCC. Our results show that miR-16 silences
COX-2 expression in hepatoma cells by two mechanisms: by
binding directly to the MRE motif in the COX-2 39-UTR and by
decreasing the levels of HuR. miRNA-16 is able to inhibit cell
proliferation, to promote cell apoptosis and to suppress the ability
of WRL68 hepatoma cell line to develop tumors in nude mice
partially through targeting COX-2 expression. Moreover a re-
duced miR-16 expression tends to correlate to high levels of COX-
2 protein in liver from patients affected by HCC. Our data suggest
an important role for miR-16 in HCC and implicate the potential
therapeutic application of miR-16 in those HCC with a high
COX-2 expression.
Materials and Methods
Chemicals
Antibodies were from Santa Cruz Laboratories (Santa Cruz,
CA, USA), Sigma Chemical Co. (St. Louis, MO, USA), Cell
Signaling (Boston, MA, USA), Abcam (Cambridge, UK) and
Cayman Chemical (Ann Arbor, MI, USA). Prostaglandin E2
(PGE2) was from Cayman Chemical. Reagents were from Roche
Diagnostics (Mannheim, Germany) or Sigma Chemical Co.
Reagents for electrophoresis were obtained from Bio-Rad
(Hercules, CA, USA). Tissue culture dishes were from Falcon
(Becton Dickinson Labware, Franklin Lakes, NJ, USA). Tissue
culture media were from Gibco (InvitrogenTM, Grand Island, NY,
USA).
Patients
Seven individual tumoral and paired non-tumoral HCC human
samples were obtained from de Spanish Tumor Bank Network of
the Centro Nacional de Investigaciones Oncolo´gicas (CNIO).
Institutional review board approval (NuPI. CEI PI 20_2011) was
obtained for these studies from Comite´ de la Investigacio´n y de
Bienestar Animal of CNIO and all participants provided written
informed consent. Tissues were evaluated by pathologists by
means of hematoxylin/eosin staining. Tissue was snap-frozen in
liquid nitrogen and total RNA and protein were isolated as
described below.
Cell Culture
The cell lines WRL68, HepG2 and Hep3B were purchased
from the American Type Culture Collection, ATCC (Manassas,
VA, US). All these cells lines were authenticated by ATCC and
were expanded twice, and stored in liquid N2. Expansions from
these clones were used up to 6 months in culture. PLC/PRF/5
[30] was kindly provided by Dr. C Perret (Institut Cochin, CNRS
UMR8104, University Paris-Descartes, Paris, France) and HuH-7
[31] by Dr. M. Kern (Department of General Pathology,
University Hospital Heidelberg, Heidelberg, Germany). WRL68
was derived from human liver embryo. HepG2, Hep3B and HuH-
7 are well differentiated hepatocellular carcinoma cell lines and
PLC/PRF/5 is a malignant liver cancer with HBsAg positive cell
line. Cells were grown on Falcon tissue culture dishes in EMEM or
DMEM supplemented with 10% FBS and antibiotics (50 mg each
of penicillin, streptomycin and gentamicin per ml) at 37uC in
a humidified air 5% CO2 atmosphere. Human hepatocytes were
from HPCH10 CryostaXTM, Single-freeze Cryopreserved Pooled
Human Hepatocytes (Xenotech, Lenexa, KA, USA).
RNA Extraction and Quantitative Real-time PCR Analysis
Total RNA from HCC cells or human biopsies was extracted by
using TRIzol reagent (Invitrogen, Grand Island, NY, USA). RNA
(1 mg) was reverse transcribed using a Transcriptor First Strand
cDNA Synthesis Kit following manufacturer’s indications (Roche
Applied Science). For quantification of mature miRNAs, total
RNA was extracted using the miRNeasy Mini Kit (Qiagen,
Valencia, CA, USA). RNA (500 ng) was polyadenylated and
reverse- transcribed to cDNA using the NCodeTM miRNA first-
strand cDNA synthesis kit (Invitrogen) in accordance with the
manufacturers instructions. The cDNA was used as template for
real-time PCR through Taqman probes. Primers for COX-2
(Hs00153133-m1) and 36b4 (Hs99999902-m1) were from Applied
Biosystems (Carlsbad, CA, USA). Real-time PCR was performed
using a MyiQ detection system (Bio-Rad) and thermocycling
parameters were 95uC for 10 min, 50 cycles of 95uC for 15 s
followed for 60uC for 1 min and finally 95uC for 1 min. Each
sample was run in triplicate and was normalized to 36b4 mRNA.
The replicates were then averaged, and fold induction was
determined in a DDCt based fold-change calculations.
Levels of miRNAs were quantified using the FastStart Universal
SYBR Green Master (Roche) with the universal reverse primer
provided in the kit and the following forward primers; hsa-miR-16:
59- TAGCAGCACGTAAATATTGGCG -39; hsa-miR-26b: 59-
CGCTTCAAGTAATTCAGGATAGGT -39; hsa-miR-199a: 59-
CCCAGTGTTCAGACTACCTGTTC -39; hsa-miR-101: 59-
CCGGTACAGTACTGTGATAACTGAA -39; hsa-miR-21: 59-
CGGTAGCTTATCAGACTGATGTTGA -39 and hsa-miR-
122: 59- TGGAGTGTGACAATGGTGTTT -39. Thermocycling
parameters were 95uC for 3 min and 40 cycles of 95uC for 15 s
followed by 60uC for 30 sec. The expression of miRNAs was
normalized against U6 snRNA levels (U6 primers: forward 59-
CTTCGGCAGCACATATACT -39; reverse 59- AAAATATG-
GAACGCTTCACG -39). Melting curve analysis was performed
to confirm the specificity of the PCR products.
The miRNAs (miR-16, miR-26b, miR-101, miR-199a, miR-
122 and miR-21) were selected by using miRWalk computational
analyses, that covers miRNA-targets interactions information
produced by 8 established miRNA prediction programs on 3’
UTRs of all known genes of Human, Mouse and Rat, i.e.,
RNA22, miRanda, miRDB, TargetScan, RNAhybrid, PITA,
MiR-16 Downregulates COX-2
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e50935
Figure 1. miR-16 and COX-2 correlate inversely in HCC cell lines. Cells were plated in 100-mm dishes and grown to 60–70% confluence in
culture medium supplemented with 10% FBS. (A) Total cellular extracts were prepared from HCC cells and protein (30–50 mg/lane) was analyzed by
Western blot. A representative Western blot showing COX-2 protein. The expression of target protein was normalized to that of a-tubulin.
Densitometric analysis of COX-2 expression (black bars) is referring to HH as 1 and expressed as relative expression (RE). Total RNA was prepared from
HCC cell lines and COX-2 mRNA was analyzed by real-time PCR. COX-2 mRNA amounts (white bars), normalized to the expression of 36b4 mRNA, and
miR-16 expression (grey bars), normalized against U6 RNA levels, were calculated. Values represent fold change relative to human hepatocytes (HH)
as 1. Data are reported as means6SD of three independent experiments. **p,0.01 and *p, 0.05 vs. the HH. (B) The inverse correlation between COX-
2 protein/mRNA ratio and miR-16 expression in HCC cells is graphically depicted. The coefficient of determination (R2) was calculated.
doi:10.1371/journal.pone.0050935.g001
Table 1. Expression of selected miRNAs is evaluated in HCC cell lines.
Cell Lines
miR-16 (R2 = 0.86) miR-26b (R2 = 0.43) miR-101 (R2 = 0.71)
p=0.016 p= 0.297 p= 0.018
HH 1 1 1
HepG2 0.00860.002 0.02360.004 0.14160.003
HuH-7 0.30960.150 0.11460.100 0.57360.250
PLC-PRF 0.60160.300 0.021.60.015 0.38360.800
WRL68 0,66160.234 0.01960.009 0.45160.315
Hep3B 1.57860.015 0.68260.261 1.95660.394
miR-199a (R2 = 0.49) miR-122 (R2 = 0.03) miR-21 (R2 = 0.02)
p=0.226 p= 0.241 p= 0.919
HH 1 1 1
HepG2 0.58360.056 0.00167.65E-05 1.50160.121
HuH-7 1.08460.430 0.02860.005 1.55860.313
PLC-PRF 0.70260.359 0.00461.91E-05 1.13060.600
WRL68 0.47960.171 0.00166.32E-05 0.99760.006
Hep3B 2.32160.380 0.01260.003 1.74160.154
The miRNAs (miR-16, miR-26b, miR-101, miR-199a, miR-122 and miR-21) were selected by using miRWalk computational analysis as described in Methods. The
expression profile was analyzed in HCC cell lines using real-time PCR, normalized against U6 RNA levels and refers to human hepatocytes (HH) as 1. COX-2 protein/
mRNA ratio was compared to miRNAs expression in HCC cells and the coefficient of determination (R2) was calculated.
doi:10.1371/journal.pone.0050935.t001
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PICTAR, and Diana-microT, and comparing the obtained results
with data collected from the literature.
Western Blot Analysis
Extracts from cells (2–36106) or from liver tissue were obtained
as previously described [32]. For Western blot analysis, whole-cell
extracts were boiled for 5 minutes in Laemmli sample buffer, and
equal amounts of protein (20–30 mg) were separated by 10–15%
SDS-polyacrylamide electrophoresis gel (SDS-PAGE). The rela-
tive amounts of each protein were determined with the following
polyclonal or monoclonal antibodies: COX-2 (Cayman 160107
and Santa Cruz sc-1747), a-tubulin (Sigma T9026), HuR (Santa
Cruz sc-5261), Ago2 (Abcam AB57113) and Caspase-3 (Cell
Signaling 9662). After incubation with the corresponding anti-
rabbit or anti-mouse horseradish peroxidase conjugated secondary
antibody, blots were developed by the ECL protocol (GE
Healthcare, Chalfont St Giles, UK). Target protein band densities
were normalized with a-tubulin. The blots were revealed, and
different exposition times were performed for each blot with
a charged coupling device camera in a luminescent image analyzer
(Gel-Doc, Bio-Rad) to ensure the linearity of the band intensities.
Densitometric analysis was expressed in arbitrary units.
Determination of Metabolites
PGE2 was determined in culture media by specific immunoas-
say (Arbor Assays, Ann Arbor, MI, USA). Protein levels were
determined with Bradford reagent (Bio-Rad).
Transfection, Constructs and Luciferase Reporter Assay
The miR-16 precursor (PM10339), which was a double-
stranded RNA mimicking the endogenous mature miRNA, the
miR-16 inhibitor (In-miR-16, AM10339) which was a single
stranded nucleic acid designed to specifically bind to and inhibit
endogenous microRNA molecule, their negative controls (miR-
NC, AM17110; In-miR-NC, AM17010) and anti-COX-2 siRNA
(siCOX-2) (positive control, forward 59- GGGCUGUCC-
CUUUACUUCAtt -39and reverse 59- UGAAGUAAAGGGA-
CAGCCCtt-39) were purchased from Ambion (Austin, TX, USA).
pPyCAGIP-hCOX-2 was prepared as described previously [33].
Briefly, human COX-2 ORF was amplified by PCR from human
full-length COX-2 cDNA cloned into pcDNA1/Amp, and then,
was subcloned into XhoI-NotI restriction site of pPyCAGIP vector.
WRL68 and Hep3B cells were seeded in a 6-well plate
(36105cells/well) at 70% confluence. After 24 h, cells were
transfected with 50 nM of miR products or 30 nM siCOX-2
using lipofectamine 2000 (Invitrogen, USA) according to the
manufacturers instructions. After 6 h of incubation at 37uC,
transfection medium was replaced with 2 ml of complete medium
containing 10% FBS. For the analysis of COX-2 mRNA or
protein decay, 5 mg/ml actinomycin-D or 10 mg/ml cyclohexi-
mide (Sigma, USA) were added after transfection. Cells were
lysated after 48 h for Western blot and RT-PCR analyses.
To determine whether COX-2 mRNA was located in
processing bodies, p-bodies (PB), as a consequence of translational
repression, digitonine permeabilization and cellular fractionation
of Hep3B cell lines were performed since PB are enriched in the
pellet fraction [34]. Hep3B cell lines were transfected with miR-16
or In-miR16 48 hours prior to harvesting at a final concentration
of 50 nM. Cells were harvested by trypsinization, washed with
cold phosphate buffered saline (PBS) and resuspended in Buffer C
[250 mM sucrose, 10 mM Tris-HCl pH 7.5, 25 mM KCl, 5 mM
MgCl2, 2 mM DTT, 30 U/ml RNasin, and 0.1% v/v phospha-
tase-protease inhibitor cocktail (Sigma) containing 50 mg/ml
digitonin (Sigma)]. After incubation on ice for 15 min, samples
were centrifuged at 1,000 g for 5 min at 4uC. The supernatant was
recentrifuged at 14,000 g at 4uC for 5 min and saved as a soluble
fraction. The pellet from 1,000 g centrifugation was washed with
Buffer C without digitonin and saved as a cell debris pellet. RNA
was isolated from each fraction with Trizol reagent and was used
for RT-PCR. 59-39 exonucleasa (Xrn1) primers; F:GAGAAGC-
GATTATTGGAAGCCA and R:GCACATTAGGCACTCAC-
TATGTT were used as PB marker.
Using several programs (RNAhybrid, PITA, and RNA22), miR-
16 was predicted to associate with the 39UTR region of COX-2 to
different MRE motifs (Table S1). In the present report, miR-16
target site prediction for COX-2 was performed using RNAhybrid
[35] and we found one predicted MRE for miR-16 at positions
1195–1217 taking as position 1 the beginning of the 39 UTR
region. The 39-UTR sequences of COX-2 were retrieved using
Ensembl Data base (available: http://www.ensembl.org). Human
miRNA sequences were downloaded from the miRBase website
(available: http://www.mirbase.org). A fragment of 39UTR COX-
2 mRNA (region 1195–1217, from NM_000963) which include
the MRE binding site for miR-16, and a mutant variant were
cloned into pGL3-Promoter vector (pGL3-empty, Promega, USA)
downstream firefly luciferase gene (SacI, HindIII sites) to obtain the
luciferase reporter constructs (pGL3-seed and pGL3-mut, re-
spectively). Sequences cloned: 59-ctttatctcagtcttgaagccaattcag-
taggtgcattggaatcaagcctga-39 (seed); 59-ctttatctcagtcttgaataaccttcag-
gagggtaattggaatcaagcctga-39 (mut).
A DNA fragment containing 2.5 kb corresponding to the full
length 39UTR region of the human COX-2 gene was amplified by
PCR and cloned into the pGEM-T easy vector (Promega) to
construct pGEMCOX-2/39UTR. The fragment was obtained by
XbaI/BamHI digestion and subcloned in the pGL3-Promoter
vector (pGL3-empty, Promega) to construct the pGL3-UTR
vector. Mutagenesis was performed by means of the QuickChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA. USA)
using pGEMCOX-2/39UTR as a template. All the constructions
were confirmed by nucleotide sequencing.
Cells (36104 cells/well) were seeded in 24-wells plate and
transfected for 6–12 h with pGL3-empty (750 ng), pGL3-seed
(750 ng), pGL3-mut (750 ng), pGL3-UTR (750 ng), pGL3-UTR
mut (750 ng), pRL-SV40 vector (50 ng, Promega, USA), miR-16
(50 nM), In-miR-16 (50 nM) or miR-NC (50 nM) or a different
combinations of them using lipofectamine 2000 reagent protocol.
Cells were harvested 48 h after transfection and cell lysates were
used for Dual-LuciferaseH Reporter Assay System analysis,
according to the manufacturer’s instructions (Promega, USA).
HuR expression vector, pcDNA3-HuR-GFP, was kindly provided
by Dr.M. Gorospe (Laboratory of Molecular Biology and
Figure 2. miR-16 regulates COX-2 expression in HCC cell lines. WRL68 and Hep3B cells were transfected with: 30 nM siRNA anti-COX2 (siCOX-
2) or 50 nM of miR-16, miR-16 inhibitor (In-miR-16), miR negative control (miR-NC) or miR negative control inhibitor (In-miR-NC). (A–B) COX-2 protein
was analyzed by Western blot 48 h after transfection and normalized against a-tubulin protein. COX-2 mRNA and miR-16 expression were analyzed
by real-time PCR. COX-2 mRNA and miR-16 expression were normalized against 36b4 mRNA and U6 RNA levels, respectively. Relative expression of
each sample refers to control as 1 (cells transfected only with lipofectamine). (C–D) PGE2 concentration was determined by enzyme immunoassay in
the supernatant of the cells. Data are reported as means6SD of four independent experiments. *p, 0.05 vs. the control condition and # p, 0.05 vs.
the miR-16 transfection condition.
doi:10.1371/journal.pone.0050935.g002
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Figure 3. miR-16 binds COX-2 mRNA and inhibits its translation. (A) WRL68 cell extracts (500 mg per lane) were immunoprecipitated with
Ago-2 or IgG antibodies. Bound RNA was harvested with TRIzol reagent, reverse transcriptased, and PCR amplified with COX-2 primers. PCR products
were visualized by electrophoresis in SYBR Safe DNA gel stain agarose gels. The presence of COX-2 mRNA in WRL68 cell transfected with miR-16 or
Lipofectamine after Ago2 immunoprecipitation was assessed, and fold differences were plotted. Input, total mRNA in cell extract; and control, bound
mRNA after immunoprecipitation with IgG antiboby. (B) Scheme of pGL3-empty, pGL3-seed and pGL3-mut reporter vectors. In pGL3-seed, the
putative binding site of miR-16 on COX-2 mRNA 39-UTR region (as detected by RNAhybrid software) was introduced downstream luciferase gene. In
pGL3-mut this region was mutated in order to avoid the binding between miR-16 and Luc mRNA. (C–D) A luciferase assay was carried out on HuH-7
and HepG2 cell lines using pGL3-seed and pGL3-mut reporter vectors. Firefly luciferase activity was evaluated 48 h after co-transfection with pGL3-
MiR-16 Downregulates COX-2
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Immunology, NIA-IRP, NIH, Baltimore, USA). When trans-
fection was performed with pcDNA3-HuR-GFP (4 mg) and
pPyCAGIP-hCOX-2 or control vector (4 mg) cells were seeded
in 6-wells plate.
Immunoprecipitation and PCR Analysis
The binding of miR-16 to COX-2 mRNA, HuR to COX-2
mRNA and the binding of HuR to miR-16 were analyzed by
immunoprecipitation and PCR analysis. The immunoprecipita-
tion was carried out in the lysis buffer (10 mM Tris/HCl, pH 8,
150 mM NaCl, 1% NP40, 0.1% azide, and protease inhibitor
cocktail). Total crude extracts (500 mg) from WRL68 and Hep3B
cells were immunoprecipitated with 10 mg Ago2, HuR, or IgG
antibody and mixed 2 hours at 4uC. An equal volume of protein
A/G sepharose was added per immunoprecipitation and mixed
overnight at 4uC. The protein/G sepharose was pelleted at
1500 rpm for 2 minutes at 4uC. For the elution of bound RNA,
beads were resuspended in the lysis buffer described above,
supplemented with 10 mg tRNA from Escherichia coli and 80 mg of
proteinase K. The mixture was incubated at 50uC for 45 minutes.
The RNA was purified using TRIzol reagent (Invitrogen,
Carlsbad, CA), reverse transcriptased and PCR amplified with
COX-2, miR-16, U6 or actin primers. The PCR reaction was
performed at 95uC for 5 min, followed by 30 cycles of 95uC for
30 s, 52uC for 30 s, and 72uC for 1 min, with the following
primers; hCOX-2 forward 59- ATCTACCCTCCT-
CAAGTCCC-39and reverse 59- TACCAGAAGGGCAGGATA-
CAG-39, actin forward 59- GCTCACGGAGGCACCCCTGAA -
39and reverse 59- CTGATAGGACATTGTTAGCAT -39, miR-
16 forward 59- TAGCAGCACGTAAATATTGGCG -39and the
universal reverse primer provided in the NCodeTM miRNA first-
strand cDNA synthesis kit (Invitrogen), U6 snRNA forward 59-
CTTCGGCAGCACATATACT -39and reverse 59- AAAA-
TATGGAACGCTTCACG -39. PCR products were visualized
by electrophoresis in SYBR Safe DNA gel stain (Invitrogen)
agarose gels.
Analysis of Cell Proliferation
Cell proliferation was determined by the MTT (3-[(4, 5-
dimethylthiazol-2-yl)-2, 59diphenyltetrazolium bromide]) assay
(Sigma). Cells (86103) were seeded on 96-well plates in DMEM
supplemented with 10% FBS. After transfection with different
conditions, cells were treated with 20 ml of MTT solution (2 mg/
ml) for 4 h at 37uC. The medium was removed and DMSO was
added to dissolve the blue formazan residue. The optical density
was measured at 570 nm.
Evaluation of Apoptosis
Apoptosis was detected by flow cytometry using Annexin V-
FITC Apoptosis Detection Kit (BD Pharmingen, San Diego,
CA, USA). Briefly, cells were collected and washed in cold PBS.
After centrifugation at 4uC for 5 min at 1000 rpm, cells were
double stained with Annexin V-FITC and PI for 15 min at
room temperature in the dark. Early apoptosis is defined by
Annexin V+/PI- staining and late apoptosis is defined by
Annexin-V+/PI+ staining as determined in a Cytomics FC500.
Analysis of Tumorigenicity in Nude Mice
Female athymic nu/nu mice (6 weeks old) were obtained from
Charles River Laboratories (Wilmington, MA). All the experi-
ments were performed in accordance with the animal care
guidelines of the European Union (2010/63/EU), and approved
by the Bioethical Committee from Consejo Superior de
Investigaciones Cientı´ficas (reference project SAF2010/16037).
The animals were kept under pathogen-free conditions and
were given an autoclaved standard diet and water ad libitum and
treated according to the Institutional Care Instructions (Bio-
ethical Commission from Consejo Superior de Investigaciones
Cientı´ficas, CSIC, Spain). WRL68 cells were transfected in vitro
with 50 nM miR-NC or miR-16 and pPyCAGIP-hCOX-2
ORF (hCOX-2 expression vector lacking COX-2 39 UTR) by
using lipofectamine 2000. At 24 h after transfection, 56106
viable cells suspended in PBS were injected subcutaneously into
both flanks of the nu/nu mice (5 mice per group). Tumor
growth was measured every 2 or 3 days. At 21 days after
injection, mice were killed and tumors were weighed after
necropsy. Tumor volume (V) was monitored by measuring the
length (L) and width (W) with calipers and calculated with the
formula (L6W2)60.5.
Data Analysis
Data are expressed as mean 6 S.D. (n ranged from three to five
independent experiments). Statistical significance was estimated
with the Student’s two-tailed t test for unpaired observations,
Spearman r test for nonparametric correlations and the Mann-
Whitney U test was used for ordinal variables using the statistical
software GraphPad Prism 5. A p value , 0.05 was considered
significant.
Results
miR-16 and COX-2 Correlate Inversely in Hepatoma Cell
Lines
To examine whether COX-2 expression is under the control of
miRNAs, we determined the expression pattern of COX-2 and
selected miRNAs in four hepatoma (HCC) cell lines (HepG2,
PLC/PRF/5, HuH-7, Hep3B) and in a cell line derived from
human liver embryo (WRL68), using human hepatocytes (HH) as
control (Fig. 1A). We found that each cell line expresses different
levels of COX-2 protein and mRNA. WRL68 exhibited the
highest COX-2 mRNA levels whereas HepG2 and PLC/PRF/5,
two differentiated liver carcinomas, showed low levels of COX-2
mRNA and protein (Fig. 1A). The expression profile of six
miRNAs (miR-16, miR-26b, miR-101, miR-199a, miR-122 and
miR-21) was analyzed in HCC cell lines (Table 1). In almost all
HCC lines analyzed, miR-16 expression was lower than in control
hepatocytes (HH), whereas COX-2 protein levels were higher
(Fig. 1A). We decided to compare the COX-2 protein/mRNA
ratio (as an index of translational inhibition) of the cell lines with
the selected miRNAs levels. Among the six miRNAs analyzed, the
expression of miR-16 showed the highest inverse correlation with
the COX-2 protein/mRNA ratio (R2 = 0.858, p = 0.016) (Fig. 1B),
suggesting that miR-16 is involved in COX-2 regulation in
hepatoma cell lines.
empty/seed/mut (750 ng), miR-16 (50 nM), In-miR-16 (50 nM) and miR-NC (50 nM) as indicated. Data were normalized against renilla luciferase
activity (all samples were co-transfected with 50 ng pRL vector and refer to the positive control, pGL3 empty vector). Data are reported as means6SD
of three independent experiments. *p, 0.05 vs. the pGL3-empty condition and # p, 0.05 vs. the miR-16 transfection condition.
doi:10.1371/journal.pone.0050935.g003
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miR-16 Regulates COX-2 Expression in HCC Cell Lines
Major approaches to validate miRNA targets use in vitro gain-
of-function and loss-of-function analyses. We overexpressed
miR-16 in HCC cell lines and examined whether it decreases
endogenous COX-2 levels. The effect of miR-16 transfection on
COX-2 protein expression was evaluated in WRL68 and
Hep3B cells and it was compared to one positive control, cells
transfected with siCOX-2, and with two different negative
controls, cells treated only with lipofectamine and cells
transfected with miR-NC. As a further control, the effect of
both miR-16 and miR-NC inhibitors were analyzed. WRL68
and Hep3B cells were chosen since they express higher levels of
COX-2 protein. miR-16 caused a decrease in COX-2 protein
levels within 48 h of transfection in both cell lines (Fig. 2A–B).
Moreover, the transfection of In-miR-16 induced an increase of
COX-2 protein mainly in Hep3B cells. COX-2 mRNA levels
were also evaluated and no significant changes was observed
following the different treatments with the exception of siCOX-
2 transfection (Fig. 2A–B). These results provide further
evidence that COX-2 mRNA is post-transcriptionally controlled
by miR-16. Released PGE2 levels are in good agreement with
COX-2 protein changes (Fig. 2C–D).
miR-16 Binds COX-2 mRNA and Inhibits its Translation
To establish whether the effect of miR-16 on COX-2
expression was mediated through a direct miRNA:mRNA
interaction, we performed a RNA immunoprecipitation (RNA-
IP) assay in WRL68 cells transfected with miR-16. Immuno-
precipitation of total lysates was carried out with an antibody
against Argonaute 2 (Ago2), a major component of the
microRNA associated to multiprotein RNA-induced-silencing
complex (RISC) [36]. As shown in Fig. 3A, COX-2 mRNA was
present in the Argo2 immunoprecitation samples where miR-16
was expressed whereas capture of the negative control actin
mRNA was unchanged. Using several programs (RNAhybrid,
PITA, and RNA22), miR-16 was predicted to associate with the
39UTR region of COX-2 to different MRE motifs (Table S1)
and we found one predicted MRE for miR-16 at positions
1195–1217 taking as position 1 the beginning of the 39 UTR
region. To ensure that miR-16 can bind to this predicted region
and cause translational repression, we performed a luciferase
reporter gene assay in HuH-7 and HepG2 cells with low levels
of miR-16. We cloned the 39UTR region of COX-2 containing
the miR-16 putative binding site (seed region) and a mutant
variant downstream the Luc gene in pGL3-vector (pGL3-seed
and pGL3-mut, respectively) (Fig. 3B). The luciferase activity
significantly decreased after cotransfection with both pGL3-seed
and miR-16, when compared to positive control (cells
transfected only with pGL3-seed). The transfection of In-miR-
16 increased the luciferase activity while the transfection of
miR-NC had no effects. Moreover, we did not observe
variations of the luciferase activity in cells cotransfected with
pGL3-mut and miR-16, in comparison to cells transfected only
with pGL3-mut (Fig. 3C–D). The results suggest that miR-16
could specifically bind to the 39UTR region of COX-2 and
represses COX-2 translation reinforcing the hypothesis that
COX-2 mRNA is a direct target for miR-16. The effect was
similar using 39 UTR full length region of COX-2 (Figure S1).
To further support the hypothesis that miR-16 is involved in the
down-regulation of COX-2 translation, we tested the expression of
COX-2 in Hep3B cells after transfection with siCOX-2 or miR-
16, in the presence of the transcription inhibitor actinomycin-D.
We found a decrease of COX-2 protein in both cases (Fig. 4A–B).
However, siCOX-2 induced a rapid decay of COX-2 mRNA (t1/
2 = 3 h) while the transfection of miR-16 did not show significant
mRNA decay when compared to negative controls (cells treated
only with lipofectamine and cells transfected with miR-NC; t1/
2 = 7 to 9 h) (Fig. 4C). We performed a similar experiment in the
presence of the protein synthesis inhibitor, cycloheximide (CHX)
and the results obtained reveal that both miR-16 and CHX
induced a rapid decay of COX-2 protein with a synergistic effect
(Fig. 4D–E). Furthermore, when Hep3B cells were treated with
digitonin and fractionated after transfection with miR-16 in order
to localize COX-2 mRNA in soluble or P-bodies (PB) fractions
[34], the amount of COX-2 mRNA present in PB was more than
90%, suggesting inhibition of translation. Instead, in Hep3B cells
transfected with lipofectamine, COX-2 mRNA is present in the
soluble fraction, where polysomes are located. A similar distribu-
tion of COX-2 mRNA was observed upon transfection of Hep3B
cells with In-miR-16 (Fig. 4F–G). The results demonstrate that
miR-16 interacts with COX-2 mRNA and promotes COX-2
protein decrease mostly through a translational repression
mechanism.
HuR Antagonizes miR-16 Activity in Regulating COX-2
Expression in Hepatoma Cell Lines
It is well known that HuR and other RNA-binding proteins
bind to and regulate COX-2 expression and determine the fate of
COX-2 translation [37,38]. However, a recent work [39] has
demonstrated that miR-16 inversely correlates with HuR protein
levels in human breast carcinoma. RNA immunoprecipitation
(RNA-IP) was performed to determine whether HuR would
associate with COX-2 and whether there is a direct interaction
between HuR and miR-16 in WRL68 cell line. As shown in
Fig. 5A, COX-2 mRNA was present in the HuR immunopreci-
pitates, whereas capture of the negative control actin mRNA was
unchanged. Moreover, when RNA-IP was performed, miR-16 was
also present in the HuR immunoprecipitates (Fig. 5B). To study
the relationship between miR-16 and HuR in HCC cell lines, we
determined whether HuR levels were altered by miR-16 trans-
fection. As shown in Fig. 5C–D, overexpression of miR-16 in
WRL68 and Hep3B cell lines led to a substantial decrease in HuR
Figure 4. Effect of miR-16 on COX-2 mRNA and protein stability. Hep3B cells were transfected with 50 nM miR-16 or miR-NC, or 30 nM
siCOX-2. 5 mg/ml actinomycin-D (Act D) or 10 mg/ml cycloheximide (CHX) were added after transfection. (A–B) COX-2 protein was analyzed by
Western blot at different time after actinomycin-D treatment. Corresponding densitometry analysis is shown and the relative expression of each
sample is related to sample at 0 h as 1. (C) mRNA COX-2 levels were analyzed by real time PCR. COX-2 mRNA amounts were calculated as relative
expression and normalized to the expression of 36b4 mRNA. Values represent fold change relative to sample at 0 h. (D–E) COX-2 protein levels were
analyzed by Western blot in the presence or absence of cycloheximide. Corresponding densitometric analysis is shown and the relative expression of
each sample is related to the value at 0 h as 1. F) Hep3B cells were transfected with 50 nM miR-16, miR-16 inhibitor (In-miR-16) or lipofectamine and
permeabilized with digitonine to obtain soluble and pellet fractions enriched in PB as described in Methods. RNA was isolated from each fraction with
Trizol reagent, reverse transcriptased, and PCR amplified with COX-2, Xrn1 and actin primers. Input, RNA extracted from cells prior to fractionation.
PCR products were visualized by electrophoresis in SYBR Safe DNA gel stain agarose gels. G) The presence of COX-2 mRNA in soluble and PB fractions
was assessed and fold differences were plotted. Data are reported as means6SD of three independent experiments. **p,0.01 and *p,0.05 vs. the
value of sample at 0 h.
doi:10.1371/journal.pone.0050935.g004
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protein levels. To determine whether miR-16-mediated COX-2
protein loss was due in part to a decrease in HuR expression,
Hep3B and WRL68 cell lines were cotransfected with miR-16 and
HuR expression vectors. As shown in Fig. 5E–F, miR-16 inhibited
the COX-2 and HuR protein levels in both cellular types;
however, in the presence of HuR, the ability of miR-16 to
downregulate COX-2 protein levels was partially abolished.
miR-16 Down Regulation of COX-2 Sensitizes HCC Cells
to Apoptosis
To further establish a functional relationship between miR-16
and COX-2, we tested whether COX-2 expression was required
to miR-16-dependent induction of apoptosis. Overexpression of
miR-16 promoted apoptosis in Hep3B hepatoma cells. However,
the effect of miR-16 on apoptosis was partially attenuated by
treatment of cells with PGE2 (Fig. 6A). Western blot analysis of
active caspase-3 showed an increase in the pro-apoptotic protein
by the effect of miR-16 and this effect was also reverted in the
presence of PGE2 (Fig. 6B). These results suggest that miR-16 may
exert its pro-apoptotic function partially through decreasing
COX-2 expression.
mir-16 Suppresses the Growth of Hepatoma Cells in vitro
and in vivo
We sought to determine whether miR-16 affects the growth of
hepatoma cell lines assessed by the MTT reduction assay. As
indicate in Fig. 7A, the growth of Hep3B cells transfected with
miR-16 was significantly decreased relative to control cells.
Transfection of the cells with miR-16 decreased cell growth up
to 40%, being restored to 70% in the presence of PGE2. To
further analyze the effect of miR-16 on hepatoma cell growth
in vivo, the WRL68 cells were transiently transfected with miR-16,
miR-NC or miR-16 together with a human COX-2 expression
vector that lacks the 39 UTR and, therefore, it cannot be regulated
by miR-16. Then the transfected cells were subcutaneously
injected into athymic nu/nu mice. The mice were followed by
the observation of xenograft growth for 3 weeks. We found that
miR-16 led to a significant reduction in the volume and weight of
the tumor comparing with the mice injected with miR-NC. COX-
2-dependent production of PGE2 increased the volume and the
weight of tumors comparing with miR-16 (Fig. 7B–C). The
expression of intratumoral miR-16, measured by real-time PCR,
increased in tumors injected with cells transfected with miR-16
compared with miR-NC without being modified by COX-2
overexpression (Fig. 7D). Moreover, human COX-2 expression
was detected in the tumors 21 days after the injection (Fig. 7E).
These results agree with the in vitro data (Fig. 7A) and suggest that
miR-16 inhibits the proliferation of hepatoma cells, among other
mechanisms, through downregulation of COX-2.
Inverse Correlation between miR-16 and COX-2
Expression is Observed in HCC Human Biopsies
Since miR-16 regulates COX-2 expression by binding to the
MRE in the 39-UTR COX-2 and by inhibition of HuR in HCC
cell lines, we evaluated the relationship between miR-16, HuR
and COX-2 mRNA/protein expression in individual tumoral (T)
and paired non-tumoral (NT) HCC human samples. COX-2
mRNA and protein were higher in NT tissue compared to T
counterparts, like HuR protein and mRNA (Figure S2A-C)
whereas miR-16 levels in HCC tissues tended to be higher in T
than in NT tissue (Figure S2D) and inversely correlated with
COX-2 protein levels (Figure S2E).
Discussion
In this study we have analyzed whether COX-2 could be
regulated by miRNAs or RNA-binding proteins in human
hepatoma cell lines and human HCC specimens and whether
COX-2 levels in human HCC correlate with an altered expression
of these miRNAs. Our results show that miR-16 directly silences
COX-2 expression in hepatoma cells and indirectly through the
downregulation of HuR. Moreover, a reduced miR-16 expression
correlates with high levels of COX-2 in liver from HCC patients.
From a functional point of view, COX-2 down-regulation by miR-
16 increased apoptosis and decreased cell proliferation in human
hepatoma cell lines.
Several lines of evidence suggest that COX-2 signaling is
implicated in hepatocarcinogenesis and that COX-2 inhibitors
prevent HCC cell growth in vitro and in animal models [40].
Increased COX-2 expression has been found in human HCC;
however, although COX-2 expression is elevated in the early
stages of HCC, many questions remain unsolved regarding the
sufficiency of COX-2 to induce/contribute to tumorigenesis. The
mechanisms regulating the expression of COX-2 at specific stages
of HCC development remain unknown. Moreover, recent data
and our present results indicate that COX-2 mRNA levels are
significantly higher in the adjacent liver than in the HCC and
lower in HCC than in nonalcoholic steatohepatitis [12]. Our
previous work demonstrated that COX-2 expression is not
sufficient to enhance malignant transformation induced by
dyethylnitrosamine in a model of transgenic mice expressing
COX-2 in hepatocytes [33]. These results suggest that COX-2
could be related to the inflammatory response occurring in the
early phases of chronic liver disease and eventually contribute to
the induction of hepatocarcinogenesis.
Several reports describe COX-2 overexpression as a critical step
contributing to various facets of colon cancer and growing
evidence indicates that this overexpression is facilitated through
loss of ARE-mediated mRNA decay [41]. In CRC cells, a variant
of COX-2 mRNA lacking the distal region of the 39UTR was
stabilized upon cell growth to confluence [28]. These findings
suggest that COX-2 mRNA can escape rapid decay through the
use of alternative polyadenylation sites, resulting in deletion of
potential 39UTR regulatory elements. This phenomenon appears
Figure 5. HuR antagonizes the downregulation of COX-2 expression caused by miR-16 in hepatoma cell lines. WRL68 cell extracts
(500 mg per lane) were immunoprecipitated with HuR or IgG antibodies. Bound RNA was harvested with TRIzol reagent, reverse transcriptased, and
PCR amplified with COX-2 (A) or miR-16 primers (B). PCR products were visualized by electrophoresis in SYBR Safe DNA gel stain agarose gels. The
abundance of the transcripts present in WRL68 cells after HuR immunoprecipitation was assessed, and fold differences were plotted. Input, total
mRNA in cell extract; unbound, unbound mRNA after immunoprecipitation with HuR antibody; bound, bound mRNA after immunoprecipitation with
HuR antibody; and control, bound mRNA after immunoprecipitation with IgG antiboby. (C–D) WRL68 and Hep3B cell lines were transfected with miR-
16 or In-miR-16 (50 nM). COX-2 and HuR protein levels were analyzed by Western Blot. (E–F) WRL68 and Hep3B cell lines were cotransfected with
miR-16 (50 nM) and pcDNA3-HuR-GFP expression vector (4 mg). COX-2 and HuR protein levels were analyzed by Western Blot. Data are reported as
means6SD of three independent experiments. *p, 0.05 vs. the control condition and # p, 0.05 vs. the miR-16 transfection condition.
doi:10.1371/journal.pone.0050935.g005
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to be common in colon cancer cells [42]. Moreover, it has been
described a common polymorphism in the 39UTR of COX-2 and
this variant is associated with lung cancer risk [43]. Nevertheless,
no data are available concerning the loss of ARE-mediated post-
transcriptional regulation of COX-2 or even polymorphisms in the
ARE elements in HCC.
There are several miRNAs abundantly expressed in adult liver
tissue [44,45] and the liver displays a differential miRNA
expression profile in HCC. Microarray analysis showed altered
expression of some miRNAs in hepatomas such as let-7a, miR-21,
miR-23, miR-130, whereas the hepato-specific miR-122a and
others were found downregulated in 70% of HCCs and in HCC-
derived cell lines [20,46,47], as reported in our data (Table 1).
Murakami et al. [48] showed a correlation between miR-222,
miR-106a, miR-92, miR-17-5p, miR-20 and miR-18 and the
degree of differentiation suggesting an involvement of specific
miRNAs in the progression of the disease. However, the molecular
mechanisms underlying transcriptional regulation of miRNA
genes in the liver remain poorly established and different
transcription factors, such as hepatocyte nuclear factor 1a, c-
myc, STAT-3 and NF-kB have been implicated [25,49]. Un-
derstanding the contribution of desregulated miRNAs to HCC
requires the identification of gene targets and in this sense, cyclin
G1 and the PTEN tumor suppressor gene have been found to be
regulated by miR-122a and miR-21, respectively [50,51].
The 39-UTR of COX-2 is complex and contains multiple copies
of AREs and MREs which, when bound to specific ARE-binding
factors or miRNAs, influence COX-2 stability and translational
efficiency [17]. Work investigating the role of COX-2 during
embryo implantation identified the miRNAs, miR-101a and miR-
199a as regulators of COX-2 [22,23]. miR-101a also controls
mammary gland development by regulating COX-2 expression
[52]. In the context of colon cancer cell lines and colon tumors,
miR-101 inhibited COX-2 translation [24]. Young et al. [36]
demonstrated that miR-16 binds the COX-2 39UTR and inhibits
COX-2 expression by promoting mRNA decay in colon cancer.
However, the functional consequences of miR-16 associated with
HCC progression have not been established. The present results
demonstrate that miR-16 regulates COX-2 expression in HCC
cells by binding directly to the MRE response element in the
COX-2 39UTR and this binding inhibits mainly COX-2 trans-
lation without affecting significantly mRNA decay. It has been
described by Huang et al. that miR-16 decreased the association
of its target mRNA with polysomes in 293T and HeLa cells by
mediating the association of mRNA with processing bodies (P-
bodies), since localization of mRNAs to these structures is
a consequence of translational repression [34]. A similar assay
has been used previously to support the PB-to-cytosol relocaliza-
tion of mRNAs relieved from miRNA repression by treatment
with antisense oligonucleotides [53]. Our results clearly show that
COX-2 mRNA was located in P-bodies (.90%) after transfection
with miR-16, inhibiting its translation.
Next, we investigated the effect of COX-2-mediated inhibition
by miR-16 in hepatocarcinogenesis. Our data show that the
ectopic expression of miR-16 repressed cell proliferation of
hepatoma cells in vitro and tumor growth in vivo, and these effects
were partially reverted by treatment with PGE2. Furthermore,
COX-2 inhibition mediated by miR-16 promoted apoptosis in
HCC cells by increasing apoptotic proteins such as caspase-3.
Various cytoplasmic proteins have been observed to bind to the
COX-2 ARE. To date, 16 different RNA-binding proteins bind
the COX-2 39UTR promoting mRNA decay, mRNA stabilization
or translational silencing [41]. The HuR protein is a ubiquitously
expressed member of the ELAV (Embryonic-Lethal Abnormal
Vision in Drosophila) family of RNA-binding proteins. HuR
contains three RNA recognition motifs with a high affinity and
specificity for AREs and its overexpression stabilizes transcripts
and promotes their translation [54]. HuR is localized pre-
dominantly in the nucleus and the ability of HuR to promote
mRNA stabilization requires its translocation to the cytoplasm.
Figure 6. Downregulation of COX-2 by miR-16 increases
apoptosis in HCC cells. Hep3B cells were transfected with 50 nM
miR-16 or In-miR-16 in the presence or absence of 5 mM PGE2 (A)
Apoptosis was measured with Annexin V-FITC Apoptosis Detection Kit
(B) Western blot analysis of caspase-3. Results are the means 6 SD of
three different experiments. *p, 0.05 vs. the corresponding control
cells # p, 0.05 vs. miR-16 condition.
doi:10.1371/journal.pone.0050935.g006
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Different cellular signals known to activate MAPK pathways, the
PI-3 kinase pathway and the Wnt signaling pathway have been
shown to trigger cytoplasmic HuR localization [55]. HuR has
been identified as a trans-acting factor that promotes COX-
expression and it is known that cytoplasmic HuR expression
correlates with poor clinical outcome and with COX-2 expression
in ovarian carcinoma [29], human keratinocytes after UVB
irradiation [56] and in colon carcinogenesis [37,57]. It is known
that HuR is overexpressed in CRC cells and tumors, where
elevated HuR levels can impede ARE-mediated decay [37].
However, the expression of HuR in HCC is not reported. HuR
binds to COX-2 and increases/maintains COX-2 expression in
HCC cells. Moreover, miR-16 is also present in the HuR
immunoprecipitated and the analysis of miR-16 predicted target
genes determined by using the algorithms miRWalk showed that
among miR-16 target genes one is HuR. miR-16 interacts with
HuR mRNA in the 39UTR and represses HuR translation in
human breast cancer cells [39]. Indeed, Dixon et al. [37] reported
a direct interaction between HuR and miR-16 promoting the
downregulation of miR-16 and targeting COX-2 in colon cancer
cells. Our data are in agreement with the proposed interaction
between miR-16 and HuR mRNA in HCC cells and suggest two
different mechanisms for miR-16 to inhibit COX-2: by binding
directly to the MRE response element in the COX-2 39-UTR and
by decreasing the levels of HuR through a direct interaction. Our
results show HuR expression, protein and mRNA, in both NT and
T tissue from HCC biopsies, paralleling COX-2 expression.
Moreover a reduced miR-16 expression tends to correlate to high
levels of COX-2 protein in liver from patients affected by HCC.
Therefore, the reduced expression of miR-16 in those HCC with
a high COX-2 expression may contribute to the promotion of cell
proliferation and the inhibition of apoptosis and consequently
facilitate the development of these types of tumors. Our data
suggest an important role for miR-16 in HCC and implicate the
potential therapeutic application of miR-16 in those HCC with
a high COX-2 expression.
Supporting Information
Figure S1 miR-16 downregulates COX-2 by binding its
39UTR. A luciferase assay was carried out on HuH-7 cell line
using pGL3-UTR reporter vectors. Firefly luciferase activity was
evaluated 48 h after co-transfection with pGL3-empty, pGL3-
UTR or pGL3-UTR mut (750 ng) and miR-16 (50 mM). Data
were normalized against renilla luciferase activity (all samples were
co-transfected with 50 ng pRL vector and refer to the positive
control, pGL3 empty vector). Data are reported as means6 SD of
three independent experiments. *p,0.05 vs. the pGL3-UTR
condition and #p,0.05 vs. the miR-16 transfection condition.
(TIFF)
Figure S2 COX-2 correlates inversely with miR-16 and directly
with HuR in HCC human biopsies. (A) COX-2 and HuR protein
expression were analyzed in both tumor (T) and their paired non
tumor (NT) tissues by Western Blot in a total of 7 pairs of matched
tissue specimens. Corresponding densitometry analysis is shown
and the relative expression of each sample is refer to that in one
non tumor tissue sample NT. (B–D) The expression of COX-2
mRNA, HuR mRNA and miR-16 were analyzed using real-time
PCR in NT and T tissue. *p, 0.05 vs. NT samples (E) COX-2
protein levels were compared to miR-16 expression in T samples.
Data were normalized against a-tubulin and U6 RNA levels,
respectively.
(TIFF)
Table S1 Several binding sites for miR-16 wihtin COX-2
39UTR, predicted by diferent algorithms. Using several programs
(RHAhybrid, RNA22, PITA, targeScan, microRNA.org), miR-16
was predicted to associate with the 39UTR region of COX-2 to
different MRE motifs. The number of binding sites, the positions
and the folding energy are indicated for each program. The
39UTR sequence of human COX-2 was retrieved using Ensembl
Data base, and miR-16 sequence for Homo Sapiens was
downloaded from mirBase website.
(DOC)
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